Scarica l'app Stockscreener
8.13
4.23%
0.33
Dopo l'orario di chiusura:
8.11
-0.02
-0.25%
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials - MSN
Gyre Therapeutics announces first doing in Phase 1 trial of F230 - TipRanks
Gyre Therapeutics (GYRE) Begins Phase 1 Trial for Pulmonary Hypertension Drug | GYRE Stock News - GuruFocus
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - TradingView
Novel PAH Drug Enters Clinical Trials in $370M China Market, Targeting Rare Disease with High Mortality - Stock Titan
Gyre Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Gyre Therapeutics Closes $23 Million Public Offering - MarketScreener
Gyre Therapeutics Raises $23M in Public Offering for MASH Clinical Trials | GYRE Stock News - Stock Titan
Northern Trust Corp Buys 8,624 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Globe and Mail
What's Behind The Big Stock Moves? GYRE, KYTX, TNGX... - Nasdaq
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday - Benzinga
GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials - marketscreener.com
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – What’s Next? - Defense World
Gyre Therapeutics announces new stock offering By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus
Gyre Therapeutics Announces Stock Offering Agreement - TipRanks
Gyre Therapeutics announces new stock offering - Investing.com
GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus
Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Gyre Therapeutics commences underwritten public offering - MSN
Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com
GYRE Announces Pricing Below Previous Closing Price | GYRE Stock News - GuruFocus
Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan
Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share - marketscreener.com
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance
Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis - marketscreener.com
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone - GuruFocus
Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial | GYRE Stock News - GuruFocus
Gyre Therapeutics tumbles after stock offering launch - TradingView
Gyre Therapeutics launches public stock offering By Investing.com - Investing.com Canada
Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock - marketscreener.com
Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth | GYRE Stock News - GuruFocus
Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025 - Nasdaq
Gyre Therapeutics Seeks Fresh Capital: Public Offering to Accelerate Phase 2 MASH Treatment Trial - Stock Titan
Breakthrough in Liver Disease: Gyre's Phase 3 Drug Achieves 53% Fibrosis Regression, First-in-Class Potential - Stock Titan
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World
Gyre Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq
1 Stock to Buy Hand Over Fist as ‘Risk On’ Sentiment Gains Momentum - The Globe and Mail
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why - Defense World
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts - Nasdaq
Earnings Flash (GYRE) Gyre Therapeutics Reports Q1 Revenue $22.1M, vs. FactSet Est of $28.4M - marketscreener.com
Taking A Look At Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE - simplywall.st
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - Yahoo Finance
Gyre Therapeutics Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
GNI Group Confirms NDA Timeline for Hydronidone - TipRanks
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):